Edwards Lifesciences Corporation (NYSE: EW) is a leading medical technology company focused on structural heart disease and critical care monitoring. Shares recently traded around $84 per share, giving the company a market capitalization of roughly $49.5B.
Edwards Lifesciences operates in highly specialized cardiovascular markets, where procedure volumes, innovation cycles, and hospital spending trends play a meaningful role in long term performance. Looking at who owns Edwards Lifesciences and recent insider trades helps show how large investors may be positioning today.
Who Are Edwards Lifesciences’ Top Shareholders?
Edwards Lifesciences’ shareholder base is led by major passive institutions. These firms tend to hold through market cycles, which can help keep long term ownership stable. Active managers adjusted in both directions, pointing to a mix of conviction and valuation discipline.
- The Vanguard Group: 70.09M shares (12.08%), ~$6.0B value. Added 359,015 shares (+0.51%).
- BlackRock Institutional Trust Company: 30.52M shares (5.26%), ~$2.6B value. Cut 370,162 shares (1.20%).
- State Street Investment Management: 25.62M shares (4.41%), ~$2.2B value. Cut 14,746 shares (0.06%).
- Wellington Management Company: 20.80M shares (3.59%), ~$1.8B value. Added 977,933 shares (+4.93%).
- J.P. Morgan Asset Management: 17.92M shares (3.09%), ~$1.5B value. Cut 2.17M shares (10.80%).
- Jennison Associates: 13.96M shares (2.41%), ~$1.2B value. Added 2.29M shares (+19.60%).
- Fidelity Management & Research: 13.03M shares (2.25%), ~$1.1B value. Added 10.73M shares (+466.56%).
- Geode Capital Management: 12.84M shares (2.21%), ~$1.1B value. Added 114,729 shares (+0.90%).
- Walter Scott & Partners: 9.96M shares (1.72%), ~$849M value. Added 1.05M shares (+11.73%).
- Union Investment Privatfonds GmbH: 8.60M shares (1.48%), ~$734M value. Added 19,169 shares (+0.22%).
The presence of large passive holders provides a stable ownership base, while selective buying and trimming among active managers suggests investors are closely weighing valuation and execution. For investors, this ownership mix signals continued institutional engagement without a clear consensus shift.
Hedge Fund Highlights
Squarepoint Ops LLC, founded by Guilherme Schmid, increased its Edwards Lifesciences position by about 228%, bringing its stake to roughly $17.7M value. The move may reflect growing optimism around structural heart procedure volumes.
Jane Street Group, co-founded by Rob Granieri, boosted its holdings by around 183% and now owns approximately $121M value of Edwards Lifesciences stock, making it one of the larger active hedge fund positions.
Kingdon Capital Management, led by founder Mark Kingdon, lifted its stake by about 175% to roughly $19.6M value, a notable increase following recent share price volatility.
Schonfeld Strategic Advisors, founded by Steven Schonfeld, raised its position by around 77% to approximately $16.8M value. For investors, hedge fund activity appears selectively constructive, though positioning remains diversified rather than concentrated.
Track the top shareholders of over 50,000 global stocks (It’s free) >>>
Edwards Lifesciences’ Recent Insider Trades
Insider trades can offer context on how executives may be managing personal exposure, though they do not necessarily reflect views on near term performance. Recent filings for Edwards Lifesciences show mostly small transactions that lean toward selling.
- Wayne Markowitz (Officer): Sold 650 shares at ~$77.57.
- Andrew M. Dahl (Officer): Sold 262 shares at ~$77.57.
- Daveen Chopra (Officer): Sold 2,500 shares at ~$81.95; recorded shares at $0.
- Larry L. Wood (Former Officer): Sold multiple blocks of 8,950 shares; recorded shares at $0.
- Daniel J. Lippis (Officer): Sold 4,114 shares at ~$79.46 and 333 shares at ~$76.79.
- Annette Bruls (Officer): Sold 109 shares at ~$78.80.
Several filings show shares recorded at $0, which appear linked to equity awards or administrative entries rather than open market buying. For investors, insider activity appears measured and does not meaningfully change overall ownership dynamics.
See recent insider trade data for over 50,000 global stocks (It’s free) >>>
What the Ownership & Insider Trade Data Tell Us
Edwards Lifesciences remains anchored by long term institutional investors, with passive funds providing stability and active managers maintaining engagement through selective adds and trims. Hedge fund positioning leans cautiously positive, while insider activity remains modest in size.
For investors, the data suggests Edwards Lifesciences continues to be viewed as a high quality medical technology business, though investors appear to be balancing long term growth potential against valuation and execution risks.
Value Any Stock in Under 60 Seconds (It’s Free)
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
